Amarin Corp. Plcuk AMRN
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Amarin Corp. Plcuk (AMRN) is a healthcare company listed in the US with a market value of about $478M. In the twelve months to September 30, 2026 it had revenue of $176M and net income of -$19M, a net margin of -10.9%.
Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is financial health (4/5); the weakest is track record (0/5).
Key numbers: a price to free cash flow of 12.8, 5-year revenue growth of -19% a year, a 5-year average ROIC of -9%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 69% below the current price.
About Amarin Corp. Plcuk
Amarin Corp. Plcuk is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $54M in 2014 to $214M in 2025, growth of about 13.3% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 3% over three years (dilution for shareholders). It spends 9% of revenue on research and development.
Score: 1.4 / 5
Checks passed
- P/FCF below 20
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Positive free cash flow
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $176M | $214M | $229M | $307M | $369M | $583M | $614M | $430M | $229M | $181M | $130M |
| Net income | -$19M | -$39M | -$82M | -$59M | -$106M | $8M | -$18M | -$23M | -$116M | -$68M | -$86M |
| Free cash flow | $37M | — | — | — | — | — | -$22M | -$12M | -$95M | -$33M | -$72M |
| EPS (diluted) | $-0.50 | $-0.90 | $-2.00 | $-1.50 | $-2.60 | $0.20 | $-0.50 | $-0.70 | $-3.90 | $-2.50 | $-4.10 |
| Net margin | -10.9% | -18.2% | -35.9% | -19.3% | -28.7% | 1.3% | -2.9% | -5.3% | -50.8% | -37.5% | -66.4% |
| ROIC | — | -8.5% | -14.6% | -9.5% | -13.8% | 1.1% | -2.4% | -2.9% | -36.8% | -128.2% | -56.3% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 1 analysts is $13.00, 14% above the current price; targets range from $13.00 to $13.00; the consensus rating is “none”.
Frequently asked questions
Is Amarin Corp. Plcuk stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 69% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Amarin Corp. Plcuk pay a dividend?
Not currently.
Is Amarin Corp. Plcuk a good stock to buy?
We do not give buy or sell advice. Amarin Corp. Plcuk scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.